Evekeo Odt is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 4 US drug patents filed from 2019 to 2024. Out of these, 3 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 10, 2037. Details of Evekeo Odt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11896562 | Oral amphetamine composition |
Mar, 2037
(11 years from now) | Active |
| US10441554 | Oral amphetamine composition |
Mar, 2037
(11 years from now) | Active |
| US11160772 | Oral amphetamine composition |
Mar, 2037
(11 years from now) | Active |
| US10130580 | Taste-masked pharmaceutical compositions |
Apr, 2024
(1 year, 2 days ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Evekeo Odt's patents.
Latest Legal Activities on Evekeo Odt's Patents
Given below is the list of recent legal activities going on the following patents of Evekeo Odt.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 13 Feb, 2024 | US11896562 |
| Recordation of Patent eGrant | 13 Feb, 2024 | US11896562 |
| Recordation of Patent Grant Mailed Critical | 13 Feb, 2024 | US11896562 |
| Patent eGrant Notification | 13 Feb, 2024 | US11896562 |
| Mail Patent eGrant Notification | 13 Feb, 2024 | US11896562 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Feb, 2024 | US11896562 |
| Email Notification Critical | 25 Jan, 2024 | US11896562 |
| Issue Notification Mailed Critical | 24 Jan, 2024 | US11896562 |
| Application Is Considered Ready for Issue Critical | 05 Jan, 2024 | US11896562 |
| Dispatch to FDC | 05 Jan, 2024 | US11896562 |
US patents provide insights into the exclusivity only within the United States, but Evekeo Odt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Evekeo Odt's family patents as well as insights into ongoing legal events on those patents.
Evekeo Odt's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Evekeo Odt's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 10, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Evekeo Odt Generic API suppliers:
Amphetamine Sulfate is the generic name for the brand Evekeo Odt. 17 different companies have already filed for the generic of Evekeo Odt, with Alkem Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Evekeo Odt's generic
Alternative Brands for Evekeo Odt
Evekeo Odt which is used for treating Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients., has several other brand drugs in the same treatment category and using the same active ingredient (Amphetamine Sulfate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Neos Theraps Inc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Amphetamine Sulfate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||||||
|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa |
| |||||||
| Teva Womens |
| |||||||
| Tris Pharma Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Amphetamine Sulfate, Evekeo Odt's active ingredient. Check the complete list of approved generic manufacturers for Evekeo Odt
About Evekeo Odt
Evekeo Odt is a drug owned by Azurity Pharmaceuticals Inc. It is used for treating Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients. Evekeo Odt uses Amphetamine Sulfate as an active ingredient. Evekeo Odt was launched by Azurity in 2021.
Approval Date:
Evekeo Odt was approved by FDA for market use on 16 April, 2021.
Active Ingredient:
Evekeo Odt uses Amphetamine Sulfate as the active ingredient. Check out other Drugs and Companies using Amphetamine Sulfate ingredient
Treatment:
Evekeo Odt is used for treating Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients.
Dosage:
Evekeo Odt is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 10MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 15MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 20MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |